Abstract

Archives of Blood Transfusion & Disorders

Cryoprecipitate Use Still Current in Hemophiliac Patients in the Congo

  • Open or Close Ngolet LO* and Elira Dokekias A

    Clinical Hematology Unit, Marien Ngouabi University, Congo

    *Corresponding author: Ngolet LO, Clinical Hematology Unit, Marien Ngouabi University, Brazzaville, Republic of Congo. BP: 32, Republic of Congo

Submission: November 06, 2017; Published: November 13, 2017

DOI: 10.31031/ABTD.2017.01.000506

ISSN: 2578-0239
Volume1 Issue2

Abstract

Hemophiliac factor concentrates due to their high cost are not accessible for the population in low resource countries, therefore; cryoprecipitate remains the main replacement offer to hemophiliac population to control bleeding episodes.

Keywords: Cryoprecipitate; Hemophilia A; Congo

Get access to the full text of this article